Volume 17, Issue 1 (March-2025 2025)                   Iranian Journal of Blood and Cancer 2025, 17(1): 13-19 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shamsian B S, Momtazmanesh N, Molaei Tavana P, Kazemi Aghdam M, Malek F, Shirvani A, et al . Emerging Evidence of BRAFV600E in LCH: The Iranian Experience. Iranian Journal of Blood and Cancer 2025; 17 (1) :13-19
URL: http://ijbc.ir/article-1-1689-en.html
Emerging Evidence of BRAFV600E in LCH: The Iranian Experience
Bibi Shahin Shamsian1 , Nader Momtazmanesh1 , Parastoo Molaei Tavana *1 , Maryam Kazemi Aghdam2 , Fatemeh Malek1 , Armin Shirvani3 , Hossein Najmabadi4 , Parvin Rostami4 , Mozhgan Hashemieh5 , Mahnaz Jamee6
1- Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Pediatric Pathology Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran. Iran..
3- Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran. Iran.
4- Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
5- Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. & Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
6- Pediatric Nephrology Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:   (618 Views)
Introduction: Langerhans cell histiocytosis (LCH) is an inflammatory neoplasm of myeloid origin. The pathologic CD1a+/CD207+ cells are characterized when mutations in the mitogen-activated protein kinase (MAPK) pathway (particularly in BRAFV600E) are activated and involvement of pulmonary, skeletal, pituitary, and cutaneous is seen. we aimed to evaluate a cohort of pediatric LCH patients regarding BRAFV600E mutations. Methods: Three referral centers between 2009-2020 collected definite LCH patients. The patients classified by the detection of BRAFV600E mutations by real-time polymerase chain reaction (RT-PCR) assay, and comparison was done in demographic and clinical manifestations, response to therapy, and outcome.
Results: Among 50 LCH patients, 17 (34%) female and 33 (66%) male, somatic mutations in the BRAFV600E gene were detected in 30 (60%) patients and wild-type genotype was seen in 20 (40%) patients. There was remarkable higher frequency of mutation in young children (less than 8 years old particularly < 2 years, p= 0.024). In this study, 21 patients (42%) had multi-system involvement, with no significant difference between the BRAFV600E positive group (14 out of 21, 66.7%) and the BRAFV600E negative group (7 out of 21, 33.3%, p = 0.380). Among patients with risk organ involvement, the BRAFV600E mutation was present in most cases (7 out of 8), and all four patients with central nervous system involvement had this mutation. Patients with the BRAFV600E mutation showed a lower response to treatment, while those without the mutation responded significantly better to first-line therapies. Notably, 6 out of 7 patients who died had the BRAFV600E mutation.
Conclusions: In LCH patients, BRAFV600E mutation may influence the onset age, sort and intensity of clinical symptoms, level of the response to therapy, and prognosis.
Keywords: Langerhans cell histiocytosis, BRAFV600E, Mortality, Treatment
Full-Text [PDF 419 kb]   (226 Downloads)    
: Original Article | Subject: Genetics
Received: 2025/01/11 | Accepted: 2025/03/26 | Published: 2025/03/30
References
1. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood, The Journal of the American Society of Hematology. 2020 Apr 16;135(16):1319-31. [DOI:10.1182/blood.2019000934]
2. Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans'‐cell histiocytosis in adults. Medical and Pediatric Oncology: The Official Journal of SIOP-International Society of Pediatric Oncology (Societé Internationale d'Oncologie Pédiatrique. 1997 Jan;28(1):9-14. https://doi.org/10.1002/(SICI)1096-911X(199701)28:1<9::AID-MPO3>3.0.CO;2-P [DOI:10.1002/(SICI)1096-911X(199701)28:13.0.CO;2-P]
3. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood, The Journal of the American Society of Hematology. 2010 Sep 16;116(11):1919-23. [DOI:10.1182/blood-2010-04-279083]
4. Bigenwald C, Le Berichel J, Wilk CM, Chakraborty R, Chen ST, Tabachnikova A, Mancusi R, Abhyankar H, Casanova-Acebes M, Laface I, Akturk G. BRAF V600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature medicine. 2021 May;27(5):851-61. [DOI:10.1038/s41591-021-01304-x]
5. Héritier S, Emile JF, Hélias-Rodzewicz Z, Donadieu J. Progress towards molecular-based management of childhood Langerhans cell histiocytosis. Archives de Pédiatrie. 2019 Jul 1;26(5):301-7. [DOI:10.1016/j.arcped.2019.05.015]
6. Feng S, Han L, Yue M, Zhong D, Cao J, Guo Y, Sun Y, Zhang H, Cao Z, Cui X, Liu R. Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing. Orphanet Journal of Rare Diseases. 2021 Jun 11;16(1):272. [DOI:10.1186/s13023-021-01912-3]
7. Tang X, Gao J, Guo X, Wan Z, Sun JJ. Beyond BRAFV600E: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children. Cancer Medicine. 2024 Dec;13(24): e70532. [DOI:10.1002/cam4.70532]
8. Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clément C, Dijoud F. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. Journal of clinical oncology. 2016 Sep 1;34(25):3023-30. [DOI:10.1200/JCO.2015.65.9508]
9. Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine. 2015 Feb 9;212(2):281-. [DOI:10.1084/jem.2013097701202015c]
10. Zeng K, Wang Z, Ohshima K, Liu Y, Zhang W, Wang L, Fan L, Li M, Li X, Wang Y, Yu Z. BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis. Oncoimmunology. 2016 Jul 2;5(7): e1185582. [DOI:10.1080/2162402X.2016.1185582]
11. Yeh EA, Greenberg J, Abla O, Longoni G, Diamond E, Hermiston M, Tran B, Rodriguez‐Galindo C, Allen CE, McClain KL, North American Consortium for Histiocytosis. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatric blood & cancer. 2018 Jan;65(1): e26784. [DOI:10.1002/pbc.26784]
12. Thacker NH, Abla O. Pediatric Langerhans cell histiocytosis: state of the science and future directions. Clin Adv Hematol Oncol. 2019 Feb 1;17(2):122-31.
13. Schwentner R, Kolenová A, Jug G, Schnöller T, Ahlmann M, Meister B, Lehrnbecher T, Minkov M, Hutter C. Longitudinal assessment of peripheral blood BRAF V600E levels in patients with Langerhans cell histiocytosis. Pediatric Research. 2019 May;85(6):856-64. [DOI:10.1038/s41390-018-0238-y]
14. Eckstein OS, Visser J, Rodriguez-Galindo C, Allen CE, NACHO-LIBRE study group. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood, The Journal of the American Society of Hematology. 2019 Apr 11;133(15):1691-4. [DOI:10.1182/blood-2018-10-878363]
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb